Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs IAC/Interactivecorp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while IAC/Interactivecorp trades at $40.57 (market cap $3.04B). The key difference: IAC/Interactivecorp is far larger — about 3.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and IAC/Interactivecorp is more actively traded (686,384 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and IAC/Interactivecorp for 80 Days on average.
| MRVI | PPLI | |
|---|---|---|
Market Cap | $972.90M | $3.04B |
Volume | 4,325,710 | 686,384 |
Sector | Health | Media |
52-Week High | $9.00 | $47.62 |
52-Week Low | $2.83 | $31.52 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $1.08B | $3.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PPLI trades at $40.56, down 0.73% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025 despite strong gross margins of 66.35%, with valuation metrics appearing attractive at P/E of 6.91 and P/B of 0.6. Recent MGM acquisition speculation has driven significant volatility, with shares surging 11.3% on takeover rumors according to Zacks Investment Research on September 28, 2026.
The outlook remains speculative with 71% analyst buy ratings supporting potential upside from strategic developments, though fundamental weakness in recent earnings and negative cash flow trends present significant risks. Investors face binary outcomes dependent on MGM deal progression versus underlying business challenges in the media sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
